tldrdaily.news logo
Tag

Disease Modifying Therapies

All articles tagged with #disease modifying therapies

health1 year ago

"Revolutionizing Parkinson's Classification: A New Biomarker-Based Framework"

Scientists have proposed a new biological classification system for Parkinson's disease, based on specific biological changes associated with the disorder, aiming to move the field closer to precision medicine and the development of disease-modifying therapies. The new model, called SynNeurGe, classifies patients based on the presence or absence of alpha-synuclein protein clumps, detectable neurodegeneration, and Parkinson's-associated genetic mutations, providing a more holistic view of the disease and its causes. This approach could lead to more targeted treatment strategies and is considered a potential game changer for Parkinson's research and patient care.

via Parkinson's News Today|
#biological-classification#disease-modifying-therapies#health
health2 years ago

Exploring the Safety of Stopping MS Treatment in Elderly Patients

A new study led by the P-HOPER Center at the University of Houston College of Pharmacy aims to determine whether older adults with multiple sclerosis (MS) can safely stop taking disease-modifying therapies. The study, funded by a $1.6 million grant, will analyze deprescribing outcomes in elderly MS patients and evaluate the safety and effectiveness of discontinuing disease-modifying agents (DMAs) in this population. The researchers will compare outcomes for patients who continue on DMAs versus those who are deprescribed these medications, with the goal of optimizing prescribing practices and improving health outcomes and quality of life for older MS patients.

via Multiple Sclerosis News Today|
#deprescribing#disease-modifying-therapies#elderly-patients
health2 years ago

27-year-old Iowa woman faces high risk of dementia

Alyssa Nash, a 27-year-old woman from Iowa, discovered she is a carrier for a gene mutation that can cause frontotemporal dementia (FTD), an early-onset neurodegenerative disease that can start as early as 21 years old. Nash's father began to display signs of FTD when he was only 38 years old, and it took seven years before he was officially diagnosed. Nash decided to undergo genetic testing and found out she carries the gene mutation. Although there are no disease-modifying therapies currently approved by the FDA, there are several experimental therapies being studied that are designed to target specific genetic mutations for FTD.

via Fox News|
#dementia#disease-modifying-therapies#frontotemporal-dementia
health2 years ago

"Hopeful Visions for Multiple Sclerosis Future"

A person with multiple sclerosis (MS) shares their top five wishes for the future of MS, including prevention of the disease, repairing damaged myelin, approving stem cell transplants, improving MS knowledge, and using highly effective treatments as early as possible. The author emphasizes the need for better outreach for education and research to find a vaccine to prevent the Epstein-Barr virus, which is thought to be a strong risk factor for developing MS.

via Multiple Sclerosis News Today|
#disease-modifying-therapies#health#multiple-sclerosis
health2 years ago

Long-term benefits of Mavenclad for MS patients.

Real-world data from the CLASSIC-MS study showed that the benefits of Mavenclad (cladribine) were sustained for up to 15 years after its last treatment course in people with relapsing multiple sclerosis (MS). More than half of those who received the oral therapy in the clinical trials that supported its approval no longer needed further disease-modifying therapies (DMTs) and twice as many continued relapse-free over a median of 10.9 years compared with those never given it. Mavenclad is a short-course oral DMT approved for relapsing forms of MS, including relapsing-remitting MS (RRMS) and active secondary progressive MS (SPMS).

via Multiple Sclerosis News Today|
#clinical-trials#disease-modifying-therapies#efficacy